{"id":389112,"date":"2023-12-14T00:00:00","date_gmt":"2023-12-14T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfon0007-2023-biopharma-non-small-cell-lung-cancer-disease-landscape-forecast-g7-2023\/"},"modified":"2026-03-31T10:31:33","modified_gmt":"2026-03-31T10:31:33","slug":"dlsfon0007-2023-biopharma-non-small-cell-lung-cancer-disease-landscape-forecast-g7-2023","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfon0007-2023-biopharma-non-small-cell-lung-cancer-disease-landscape-forecast-g7-2023\/","title":{"rendered":"Non-Small-Cell Lung Cancer | Disease Landscape &#038; Forecast | G7 | 2023"},"content":{"rendered":"<p>The multi-billion-dollar non-small-cell lung cancer (NSCLC) market is highly dynamic, with a plethora of approved therapies but still a high unmet need. Immune checkpoint inhibitors such as Keytruda (Merck &#038; Co), which gained label expansion in January 2023 in the adjuvant setting, have broad applicability in many stages and settings of NSCLC and dominate the market, while biomarker-targeted therapeutics increasingly drive segmentation of the space. The range of drug-addressable disease drivers continues to expand, with the entry of KRAS inhibitors and the 2022 approval of Enhertu, the first targeted therapy for previously treated metastatic HER2-mutant NSCLC. Continued drug development in the biomarker and immune checkpoint inhibitor classes, plus further new market entrants, will further drive competition in this commercially lucrative market.<\/p>\n<p><strong>Questions answered<\/strong><\/p>\n<ul>\n<li>How will the recent and expected new market entrants shape the treatment landscapes across the various settings and stages (I-IV) of NSCLC?<\/li>\n<li>Which therapy options will dominate the commercially lucrative first-line metastatic NSCLC setting?<\/li>\n<li>What are the most promising pipeline products, and what is their forecast uptake and patient share in NSCLC?<\/li>\n<li>What are NSCLC\u2019s key market drivers and constraints, and how will the market evolve over the forecast period?<\/li>\n<\/ul>\n<p><strong>Product description<\/strong><\/p>\n<p><em>Disease Landscape &#038; Forecast<\/em> provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.<\/p>\n<p><strong>Solution enhancements<\/strong><\/p>\n<p>Disease Landscape &#038; Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.<\/p>\n<p>Disease Landscape &#038; Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.<\/p>\n","protected":false},"template":"","class_list":["post-389112","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-non-small-cell-lung-cancer","biopharma-therapy-areas-small-cell-lung-cancer","biopharma-date-975"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389112","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389112\/revisions"}],"predecessor-version":[{"id":576021,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389112\/revisions\/576021"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=389112"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}